Full Fed. Circ. Won't Review BMS Hepatitis Drug Patent Ruling
The full Federal Circuit refused Monday to review a decision invalidating a Bristol-Myers Squibb Co. hepatitis B drug patent as obvious, even though the compound it was based on was later...To view the full article, register now.
Already a subscriber? Click here to view full article